{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:11:56Z","timestamp":1794917516887,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Localized prostate cancer (PCa) is highly variable in their response to therapies. Although a fraction of this heterogeneity can be explained by clinical factors or genomic and transcriptomic profiling, the proteomic-based profiling of aggressive PCa remains poorly understood. Here, we profiled the genome, transcriptome, proteome and phosphoproteome of 145 cases of localized PCa in Chinese patients. Proteome-based stratification of localized PCa revealed three subtypes with distinct molecular features: immune subgroup, arachidonic acid metabolic subgroup and sialic acid metabolic subgroup with highest biochemical recurrence (BCR) rates. Further, we nominated NANS protein, a key enzyme in sialic acid synthesis as a potential prognostic biomarker for aggressive PCa and validated in two independent cohorts. Finally, taking advantage of cell-derived orthotopic transplanted mouse models, single-cell RNA sequencing (scRNA-seq) and immunofluorescence analysis, we revealed that targeting NANS can reverse the immunosuppressive microenvironment through restricting the sialoglycan-sialic acid-recognizing immunoglobulin superfamily lectin (Siglec) axis, thereby inhibiting tumor growth of PCa. In sum, we integrate multi-omic data to refine molecular subtyping of localized PCa, and identify NANS as a potential prognostic biomarker and therapeutic option for aggressive PCa.<\/jats:p>","DOI":"10.1038\/s41467-025-58569-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T22:32:53Z","timestamp":1743805973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies"],"prefix":"10.1038","volume":"16","author":[{"given":"Wei","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-8236","authenticated-orcid":false,"given":"Xin-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Xuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-0101","authenticated-orcid":false,"given":"Jian-Ping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hio-Cheng","family":"Un","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Fu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-5648","authenticated-orcid":false,"given":"Ling-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-2076","authenticated-orcid":false,"given":"Ling-Li","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-7232","authenticated-orcid":false,"given":"Zong-Ren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"58569_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA: a cancer J. Clin."},{"key":"58569_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 79, 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"key":"58569_CR3","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1200\/JCO.2011.35.1924","volume":"30","author":"MK Buyyounouski","year":"2012","unstructured":"Buyyounouski, M. K., Pickles, T., Kestin, L. L., Allison, R. & Williams, S. G. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J. Clin. Oncol. 30, 1857\u20131863 (2012).","journal-title":"J. Clin. Oncol."},{"key":"58569_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.eururo.2012.02.031","volume":"61","author":"PJ Bastian","year":"2012","unstructured":"Bastian, P. J. et al. High-risk prostate cancer: from definition to contemporary management. Eur. Urol. 61, 1096\u20131106 (2012).","journal-title":"Eur. Urol."},{"key":"58569_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","volume":"67","author":"EA Klein","year":"2015","unstructured":"Klein, E. A. et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur. Urol. 67, 778\u2013786 (2015).","journal-title":"Eur. Urol."},{"key":"58569_CR6","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","volume":"35","author":"DE Spratt","year":"2017","unstructured":"Spratt, D. E. et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J. Clin. Oncol. 35, 1991\u20131998 (2017).","journal-title":"J. Clin. Oncol."},{"key":"58569_CR7","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.19.02768","volume":"38","author":"SE Eggener","year":"2020","unstructured":"Eggener, S. E. et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J. Clin. Oncol. 38, 1474\u20131494 (2020).","journal-title":"J. Clin. Oncol."},{"key":"58569_CR8","unstructured":"The Molecular Taxonomy of Primary Prostate Cancer. Cell 163, 1011-1025 (2015)."},{"key":"58569_CR9","doi-asserted-by":"crossref","unstructured":"Clark J. P., & Cooper C. S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6, 429-439 (2009).","DOI":"10.1038\/nrurol.2009.127"},{"key":"58569_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur. Urol. 79, 263\u2013282 (2021).","journal-title":"Eur. Urol."},{"key":"58569_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn, P. et al. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur. Urol. 75, 88\u201399 (2019).","journal-title":"Eur. Urol."},{"key":"58569_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis, G. et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur. Urol. 70, 256\u2013262 (2016).","journal-title":"Eur. Urol."},{"key":"58569_CR13","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson, D. F. et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J. Clin. Oncol. 34, 2098\u20132106 (2016).","journal-title":"J. Clin. Oncol."},{"key":"58569_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","volume":"567","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y. et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567, 257\u2013261 (2019).","journal-title":"Nature"},{"key":"58569_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 179, 561\u2013577.e22 (2019).","journal-title":"Cell"},{"key":"58569_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2020.05.043","volume":"182","author":"J-Y Xu","year":"2020","unstructured":"Xu, J.-Y. et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell 182, 245\u2013261.e17 (2020).","journal-title":"Cell"},{"key":"58569_CR17","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao, L. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 184, 5031\u20135052.e26 (2021).","journal-title":"Cell"},{"key":"58569_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.eururo.2017.08.027","volume":"73","author":"S Ren","year":"2018","unstructured":"Ren, S. et al. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur. Urol. 73, 322\u2013339 (2018).","journal-title":"Eur. Urol."},{"key":"58569_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Epidemiology and genomics of prostate cancer in Asian men. Nat. Rev. Urol. 18, 282\u2013301 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"58569_CR20","volume":"5","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Updated prevalence of latent prostate cancer in Chinese population and comparison of biopsy results: An autopsy-based study. Innov. (Camb. (Mass)) 5, 100558 (2024).","journal-title":"Innov. (Camb. (Mass))"},{"key":"58569_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02188-9","volume":"21","author":"K Charmpi","year":"2020","unstructured":"Charmpi, K. et al. Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biol. 21, 302 (2020).","journal-title":"Genome Biol."},{"key":"58569_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","volume":"35","author":"A Sinha","year":"2019","unstructured":"Sinha, A. et al. The Proteogenomic Landscape of Curable Prostate Cancer. Cancer cell 35, 414\u2013427.e416 (2019).","journal-title":"Cancer cell"},{"key":"58569_CR23","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao, S. G. et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 3, 1663\u20131672 (2017).","journal-title":"JAMA Oncol."},{"key":"58569_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93\u201399 (2020).","journal-title":"Nature"},{"key":"58569_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41585-022-00588-z","volume":"19","author":"TL Pulliam","year":"2022","unstructured":"Pulliam, T. L. et al. Regulation and role of CAMKK2 in prostate cancer. Nat. Rev. Urol. 19, 367\u2013380 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"58569_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00109-023-02298-4","volume":"101","author":"V Chalfant","year":"2023","unstructured":"Chalfant, V. et al. Potential role for protein kinase D inhibitors in prostate cancer. J. Mol. Med. (Berl., Ger.) 101, 341\u2013349 (2023).","journal-title":"J. Mol. Med. (Berl., Ger.)"},{"key":"58569_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ni921","volume":"4","author":"KA Fitzgerald","year":"2003","unstructured":"Fitzgerald, K. A. et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491\u2013496 (2003).","journal-title":"Nat. Immunol."},{"key":"58569_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1126\/science.1081315","volume":"300","author":"S Sharma","year":"2003","unstructured":"Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. Sci. (N. Y., NY) 300, 1148\u20131151 (2003).","journal-title":"Sci. (N. Y., NY)"},{"key":"58569_CR29","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1093\/nar\/gkaa271","volume":"48","author":"A Bainbridge","year":"2020","unstructured":"Bainbridge, A. et al. IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway. Nucleic acids Res. 48, 5366\u20135382 (2020).","journal-title":"Nucleic acids Res."},{"key":"58569_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10555-018-9750-0","volume":"37","author":"AA Panagiotopoulos","year":"2018","unstructured":"Panagiotopoulos, A. A., Kalyvianaki, K., Castanas, E. & Kampa, M. Eicosanoids in prostate cancer. Cancer Metast. Rev. 37, 237\u2013243 (2018).","journal-title":"Cancer Metast. Rev."},{"key":"58569_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ng.3578","volume":"48","author":"CD van Karnebeek","year":"2016","unstructured":"van Karnebeek, C. D. et al. NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat. Genet. 48, 777\u2013784 (2016).","journal-title":"Nat. Genet."},{"key":"58569_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","volume":"10","author":"H L\u00e4ubli","year":"2022","unstructured":"L\u00e4ubli, H., Nalle, S. C. & Maslyar, D. Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches. Cancer Immunol. Res. 10, 1423\u20131432 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"58569_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/glycob\/cwv097","volume":"26","author":"OM Pearce","year":"2016","unstructured":"Pearce, O. M. & L\u00e4ubli, H. Sialic acids in cancer biology and immunity. Glycobiology 26, 111\u2013128 (2016).","journal-title":"Glycobiology"},{"key":"58569_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ajpa.10018","volume":"33","author":"A Varki","year":"2001","unstructured":"Varki, A. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. Am. J. Phys. Anthropol. 33, 54\u201369 (2001).","journal-title":"Am. J. Phys. Anthropol."},{"key":"58569_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14728222.2019.1667977","volume":"23","author":"A B\u00e4renwaldt","year":"2019","unstructured":"B\u00e4renwaldt, A. & L\u00e4ubli, H. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity. Expert Opin. Therap. targets 23, 839\u2013853 (2019).","journal-title":"Expert Opin. Therap. targets"},{"key":"58569_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan, S. & Paulson, J. C. Siglecs as Immune Cell Checkpoints in Disease. Annu Rev. Immunol. 38, 365\u2013395 (2020).","journal-title":"Annu Rev. Immunol."},{"key":"58569_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21550-4","volume":"12","author":"E Rodriguez","year":"2021","unstructured":"Rodriguez, E. et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat. Commun. 12, 1270 (2021).","journal-title":"Nat. Commun."},{"key":"58569_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.eururo.2014.11.038","volume":"69","author":"S Sommariva","year":"2016","unstructured":"Sommariva, S., Tarricone, R., Lazzeri, M., Ricciardi, W. & Montorsi, F. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 69, 107\u2013115 (2016).","journal-title":"Eur. Urol."},{"key":"58569_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.urolonc.2018.10.011","volume":"37","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S., Prokhnevska, N. & Kissick, H. T. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urol. Oncol. 37, 543\u2013555 (2019).","journal-title":"Urol. Oncol."},{"key":"58569_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","volume":"13","author":"ND James","year":"2012","unstructured":"James, N. D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 13, 549\u2013558 (2012).","journal-title":"Lancet Oncol."},{"key":"58569_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10555-011-9299-7","volume":"30","author":"IM Berquin","year":"2011","unstructured":"Berquin, I. M., Edwards, I. J., Kridel, S. J. & Chen, Y. Q. Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metast. Rev. 30, 295\u2013309 (2011).","journal-title":"Cancer Metast. Rev."},{"key":"58569_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.phrs.2018.02.022","volume":"131","author":"L Galbraith","year":"2018","unstructured":"Galbraith, L., Leung, H. Y. & Ahmad, I. Lipid pathway deregulation in advanced prostate cancer. Pharm. Res 131, 177\u2013184 (2018).","journal-title":"Pharm. Res"},{"key":"58569_CR43","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-18-2812","volume":"79","author":"S Li","year":"2019","unstructured":"Li, S. et al. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 79, 2580\u20132592 (2019).","journal-title":"Cancer Res."},{"key":"58569_CR44","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-13-2543","volume":"74","author":"R Jin","year":"2014","unstructured":"Jin, R. et al. NF-\u03baB gene signature predicts prostate cancer progression. Cancer Res. 74, 2763\u20132772 (2014).","journal-title":"Cancer Res."},{"key":"58569_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","volume":"5","author":"S Luszczak","year":"2020","unstructured":"Luszczak, S. et al. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduct. Target Ther. 5, 7 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"58569_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.trecan.2024.01.004","volume":"10","author":"DH Angappulige","year":"2024","unstructured":"Angappulige, D. H., Mahajan, N. P. & Mahajan, K. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression. Trends Cancer 10, 369\u2013381 (2024).","journal-title":"Trends Cancer"},{"key":"58569_CR47","first-page":"640","volume":"28","author":"OJ Adams","year":"2018","unstructured":"Adams, O. J., Stanczak, M. A., von Gunten, S. & L\u00e4ubli, H. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology 28, 640\u2013647 (2018).","journal-title":"Glycobiology"},{"key":"58569_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj1270","volume":"14","author":"MA Stanczak","year":"2022","unstructured":"Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med 14, eabj1270 (2022).","journal-title":"Sci. Transl. Med"},{"key":"58569_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790317","volume":"12","author":"EJH van Houtum","year":"2021","unstructured":"van Houtum, E. J. H., B\u00fcll, C., Cornelissen, L. A. M. & Adema, G. J. Siglec Signaling in the Tumor Microenvironment. Front. Immunol. 12, 790317 (2021).","journal-title":"Front. Immunol."},{"key":"58569_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2022.100105","volume":"14","author":"KJ Metcalf","year":"2022","unstructured":"Metcalf, K. J. et al. Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression. Matrix Biol. 14, 100105 (2022).","journal-title":"Matrix Biol."},{"key":"58569_CR51","doi-asserted-by":"crossref","unstructured":"Rodrigues E., & Macauley M. S. Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. Cancers 10, (2018).","DOI":"10.3390\/cancers10060207"},{"key":"58569_CR52","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","volume":"78","author":"C B\u00fcll","year":"2018","unstructured":"B\u00fcll, C. et al. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity. Cancer Res. 78, 3574\u20133588 (2018).","journal-title":"Cancer Res."},{"key":"58569_CR53","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184, 5482\u20135496.e5428 (2021).","journal-title":"Cell"},{"key":"58569_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinforma. 11, 367 (2010).","journal-title":"BMC Bioinforma."},{"key":"58569_CR55","doi-asserted-by":"publisher","first-page":"e15543","DOI":"10.1371\/journal.pone.0015543","volume":"5","author":"Y Hoshida","year":"2010","unstructured":"Hoshida, Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PloS ONE 5, e15543 (2010).","journal-title":"PloS ONE"},{"key":"58569_CR56","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"58569_CR57","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/pros.10283","volume":"57","author":"C Jin","year":"2003","unstructured":"Jin, C., McKeehan, K. & Wang, F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 57, 160\u2013164 (2003).","journal-title":"Prostate"},{"key":"58569_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209\u2013221 (2003).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58569-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:15:13Z","timestamp":1743866113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58569"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58569-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3189"}}